BSX Investors: Boston Scientific Class Action Lawsuit Filed. Is Your Portfolio at Risk?

SAN DIEGO—Robbins LLP has announced the filing of a class-action lawsuit against Boston Scientific Corporation (NYSE: BSX), a global developer and manufacturer of medical devices. This legal action targets investors who purchased the company’s common stock between July 23, 2025, and February 3, 2026. Individuals seeking more information about the allegations are encouraged to reach out to attorney Aaron Dumas, Jr., by submitting a form, sending an email, or calling (800) 350-6003.

Based on Ranked Stocks data, Boston Scientific (NYSE: BSX) currently holds an RS Score of 51.96, placing it in the 10.20th percentile within its country and the 7.14th percentile in its sector. The company demonstrates strong performance in Profitability, with a score of 80.40. However, it shows weaker performance in other key areas, including Valuation (46.92), Growth (14.10), Momentum (8.38), and EPS Revisions (70.00). Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.